Quantcast
Last updated on April 18, 2014 at 10:25 EDT

Latest Lapatinib Stories

2011-08-03 14:32:13

Innovative studies to prevent and slow metastatic breast cancer presented at the Era of Hope conference Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP). Approximately 6 percent of women with breast cancer will have metastatic disease upon diagnosis, and up to 30 percent of node-negative and 70 percent of node-positive...

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...

2011-06-13 07:50:26

(Ivanhoe Newswire) -- A treatment that combines a chemotherapy agent that is approved to treat breast cancer and a cancer-fighting antibody may be a promising therapy for colon cancer, according to new research. About 50,000 people die from colorectal cancer each year, and more than 150,000 cases are diagnosed annually. There are limited chemotherapy treatments available for colorectal cancer. Investigators tested the breast cancer agent lapatinib in combination with monoclonal antibody in...

2011-06-08 21:52:41

A new treatment for colon cancer that combines a chemotherapy agent approved to treat breast cancer and a cancer-fighting antibody is ready for clinical trials, according to Penn State College of Medicine researchers. More than 150,000 cases of colorectal cancer are diagnosed each year, and about 50,000 people die from colorectal cancer yearly. Currently there are limited chemotherapy treatments for colorectal cancer with little that has been in the pipeline in recent years. Wafik S....

2011-05-19 13:48:56

A subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments and may not need chemotherapy, said researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine on behalf of the Translational Breast Cancer Research Consortium in an abstract released today by the American Society of Clinical Oncology. Dr. Jenny Chang, previously with...

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-111 and MM-302, two candidates from the company's novel pipeline of five cancer therapeutics, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held April 2 "“ 6, 2011,...

2011-03-08 13:35:45

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes of targeted therapies (HER2- and PI3 kinase-targeted therapies). Therefore targeting HER3 together...

2011-03-01 08:49:06

(Ivanhoe Newswire) -- For women with aggressive early-stage breast cancer (HER2-positive disease), trastuzumab (Herceptin) given for one year after chemotherapy proved to put the women at significantly less risk of the cancer returning. The effect is long lasting, according to this study. Around 20% of women with breast cancer have HER2-positive cancer and are at high risk of cancer recurrence and of dying from the disease. Trastuzumab is a monoclonal antibody developed to block the...

2010-11-15 12:42:00

SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Breast cancer is the second leading cause of cancer related death among women, according to the...

2010-10-27 08:00:00

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly...